180 related articles for article (PubMed ID: 38156903)
1. A safety evaluation of ruxolitinib for the treatment of polycythemia vera.
Boldrini V; Vannucchi AM; Guglielmelli P
Expert Opin Drug Saf; 2024 Jan; 23(1):1-7. PubMed ID: 38156903
[TBL] [Abstract][Full Text] [Related]
2. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.
Kirito K; Suzuki K; Miyamura K; Takeuchi M; Handa H; Okamoto S; Gadbaw B; Yamauchi K; Amagasaki T; Ito K; Hino M
Int J Hematol; 2018 Feb; 107(2):173-184. PubMed ID: 28956263
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib for the treatment of patients with polycythemia vera.
Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S
Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454
[TBL] [Abstract][Full Text] [Related]
5. Achievements and future outlook for JAK inhibitors in polycythaemia vera.
Cakmak I; Harrison C
Expert Opin Pharmacother; 2023; 24(13):1491-1496. PubMed ID: 37343285
[TBL] [Abstract][Full Text] [Related]
6. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
Verstovsek S; Passamonti F; Rambaldi A; Barosi G; Rosen PJ; Rumi E; Gattoni E; Pieri L; Guglielmelli P; Elena C; He S; Contel N; Mookerjee B; Sandor V; Cazzola M; Kantarjian HM; Barbui T; Vannucchi AM
Cancer; 2014 Feb; 120(4):513-20. PubMed ID: 24258498
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
8. The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.
Ikeda K; Ueda K; Sano T; Ogawa K; Ikezoe T; Hashimoto Y; Morishita S; Komatsu N; Ohto H; Takeishi Y
Intern Med; 2017; 56(13):1705-1710. PubMed ID: 28674362
[TBL] [Abstract][Full Text] [Related]
9. Ruxolitinib (a JAK2 inhibitor) as an emerging therapy for refractory pruritis in a patient with low-risk polycythemia vera: A case report.
Al-Mashdali AF; Kashgary WR; Yassin MA
Medicine (Baltimore); 2021 Nov; 100(44):e27722. PubMed ID: 34871267
[TBL] [Abstract][Full Text] [Related]
10. JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Bose P; Verstovsek S
Blood; 2017 Jul; 130(2):115-125. PubMed ID: 28500170
[TBL] [Abstract][Full Text] [Related]
11. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.
Lin JQ; Li SQ; Li S; Kiamanesh EF; Aasi SZ; Kwong BY; Su Chang AL
J Am Acad Dermatol; 2022 Feb; 86(2):339-344. PubMed ID: 34648874
[TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
13. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.
Alvarez-Larrán A; Garrote M; Ferrer-Marín F; Pérez-Encinas M; Mata-Vazquez MI; Bellosillo B; Arellano-Rodrigo E; Gómez M; García R; García-Gutiérrez V; Gasior M; Cuevas B; Angona A; Gómez-Casares MT; Martínez CM; Magro E; Ayala R; Del Orbe-Barreto R; Pérez-López R; Fox ML; Raya JM; Guerrero L; García-Hernández C; Caballero G; Murillo I; Xicoy B; Ramírez MJ; Carreño-Tarragona G; Hernández-Boluda JC; Pereira A;
Cancer; 2022 Jul; 128(13):2441-2448. PubMed ID: 35417564
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Kiladjian JJ; Zachee P; Hino M; Pane F; Masszi T; Harrison CN; Mesa R; Miller CB; Passamonti F; Durrant S; Griesshammer M; Kirito K; Besses C; Moiraghi B; Rumi E; Rosti V; Blau IW; Francillard N; Dong T; Wroclawska M; Vannucchi AM; Verstovsek S
Lancet Haematol; 2020 Mar; 7(3):e226-e237. PubMed ID: 31982039
[TBL] [Abstract][Full Text] [Related]
15. The advantages and risks of ruxolitinib for the treatment of polycythemia vera.
Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M
Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Theocharides A; Gisslinger H; De Stefano V; Accurso V; Iurlo A; Devos T; Egyed M; Lippert E; Delgado RG; Cantoni N; Dahm AEA; Sotiropoulos D; Houtsma E; Smyth A; Iqbal A; Di Matteo P; Zuurman M; Te Boekhorst PAW
Eur J Haematol; 2024 Mar; 112(3):379-391. PubMed ID: 37899734
[TBL] [Abstract][Full Text] [Related]
17. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Passamonti F; Griesshammer M; Palandri F; Egyed M; Benevolo G; Devos T; Callum J; Vannucchi AM; Sivgin S; Bensasson C; Khan M; Mounedji N; Saydam G
Lancet Oncol; 2017 Jan; 18(1):88-99. PubMed ID: 27916398
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study.
Passamonti F; Palandri F; Saydam G; Callum J; Devos T; Guglielmelli P; Vannucchi AM; Zor E; Zuurman M; Gilotti G; Zhang Y; Griesshammer M
Lancet Haematol; 2022 Jul; 9(7):e480-e492. PubMed ID: 35597252
[TBL] [Abstract][Full Text] [Related]
19. Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
Coltoff A; Mesa R; Gotlib J; Shulman J; Rampal RK; Siwoski O; Yacoub A; Moliterno A; Yang A; Braunstein E; Gerds AT; Hobbs GS; Winton EF; Goel S; Wadleigh M; Tremblay D; Moshier E; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):697-703.e1. PubMed ID: 32624445
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
Sørensen AL; Mikkelsen SU; Knudsen TA; Bjørn ME; Andersen CL; Bjerrum OW; Brochmann N; Patel DA; Gjerdrum LMR; El Fassi D; Kruse TA; Larsen TS; Mourits-Andersen HT; Nielsen CH; Ellervik C; Pallisgaard N; Thomassen M; Kjær L; Skov V; Hasselbalch HC
Haematologica; 2020 Sep; 105(9):2262-2272. PubMed ID: 33054051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
